Immunosuppressive therapy with horse anti-thymocyte globulin and cyclosporine as treatment for fulminant aplastic anemia in children. 2014

Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
Department of Pediatrics, School of Medicine, Nihon University, 30-1 Ohyaguchi-Kamicho, Itabashi-ku, 173-8610, Tokyo, Japan, yagasaki.hiroshi@nihon-u.ac.jp.

Patients with severe aplastic anemia (SAA) and an absolute neutrophil count (ANC) of 0 typically have fatal outcomes. We defined fulminant AA (FAA) as ANC = 0 for at least 2 weeks prior to and after immunosuppressive therapy (IST). We analyzed the outcomes of 35 children with FAA among 288 children who enrolled in a prospective study for AA (AA-97 study). AA was classified as FAA (n = 35), very SAA (vSAA; n = 129), or SAA (n = 124). All of the children received the IST with horse anti-thymocyte globulin (ATG) and cyclosporine (CsA). A significantly lower response rate at 6 months was seen in children with FAA when compared to those with vSAA or SAA (40.0, 63.6, and 63.7 %, respectively; p = 0.027). Of 20 nonresponder patients in the FAA group, 11 were rescued by alternative donor transplantation, and 5 patients showed a late response after 6 months. Consequently, no significant difference was noted in overall survival when comparing the FAA, vSAA, and SAA groups (88.5, 95.8, and 96.8 %). These findings indicate that IST with ATG and CsA is justified as a first-line treatment for children with FAA who lack a human leukocyte antigen-matched sibling donor.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue
D006736 Horses Large, hoofed mammals of the family EQUIDAE. Horses are active day and night with most of the day spent seeking and consuming food. Feeding peaks occur in the early morning and late afternoon, and there are several daily periods of rest. Equus caballus,Equus przewalskii,Horse, Domestic,Domestic Horse,Domestic Horses,Horse,Horses, Domestic

Related Publications

Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
September 1998, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
April 1982, Scandinavian journal of haematology,
Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
November 2009, International journal of hematology,
Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
January 1986, Sangre,
Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
April 2021, Internal medicine (Tokyo, Japan),
Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
January 2006, Pediatric hematology and oncology,
Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
January 2000, Seminars in hematology,
Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
July 2010, Haematologica,
Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
April 2014, Haematologica,
Hiroshi Yagasaki, and Hiroyuki Shichino, and Akira Ohara, and Ryoji Kobayashi, and Hiromasa Yabe, and Shouichi Ohga, and Kazuko Hamamoto, and Yoshitoshi Ohtsuka, and Hiroyuki Shimada, and Masami Inoue, and Hideki Muramatsu, and Yoshiyuki Takahashi, and Seiji Kojima
July 2023, Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion,
Copied contents to your clipboard!